SAN FRANCISCO — It seemed like there was a point during last year’s J.P. Morgan Healthcare Conference when we all collectively realized, “Oh, 2023 is going to be another slog.” Indeed, a downturn has weighed on the biotech industry for nearly three years.
But this January, things feel different. Maybe it’s the abundance of sunlight that filled San Francisco this week. More likely, it’s the surge of deals that came in December. Whatever the reason, sentiment around Union Square in recent days was markedly more positive this year.
Most everyone I spoke to this week noticed the change in tenor. “I’m feeling a lot of good energy, honestly,” Mira Chaurushiya, managing director at VC Westlake Village BioPartners, told me Tuesday. “It’s not only what happened the last few weeks of the year, but what people are projecting moving forward.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect